Tightening the tumor-targeting abilities of checkpoint blockade immunotherapy

(American Association for the Advancement of Science) Seeking to improve upon existing checkpoint inhibitor therapies, scientists have developed a common checkpoint inhibitor (anti-PD-L1) in a nanoparticle formulation, which were activated specifically at tumor sites in mouse models of cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news